Phillips NS, Mulrooney DA, Williams AM, et al. Neurocognitive impairment associated with chronic morbidity in long-term survivors of Hodgkin Lymphoma. Blood Adv. 2023;7(23):7270-7278.

doi:10.1182/bloodadvances.2024013111

Skip Nav Destination

ERRATUM| May 28, 2024

Phillips NS, Mulrooney DA, Williams AM, et al. Neurocognitive impairment associated with chronic morbidity in long-term survivors of Hodgkin Lymphoma. Blood Adv. 2023;7(23):7270-7278.

Blood Adv (2024) 8 (10): 2398–2399.

https://doi.org/10.1182/bloodadvances.2024013111

Page 7273: in Table 1 under “Survivors N = 204,” in the row “Diagnosed with second malignancy,” the value should read “48 (24.0),” not “51 (25.0).” The corrected Table 1 is shown below:

Page 7274: in Table 2 under the “Survivors Mean (SD)” and “Controls Mean (SD)” columns, the authors misreported the means and standard deviations of the neurocognitive test at the hundredth decimal place. The corrected Table 2 is shown below:

These errors do not impact the P values, statistical significance, or relevant interpretations of the data.

© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

2024

Table 1.

Characteristics of survivors of HL and community controls

	Survivors N = 204	Controls N = 205	P value
	n (%)	n (%)	P value
Sex
Male	97 (47.5)	99 (48.3)	0.88
Female	107 (52.5)	106 (51.7)
Race
White	172 (84.3)	176 (85.9)	0.66
Other	32 (15.7)	29 (14.1)
Smoking Status
Current	39 (19.1)	29 (14.3)	0.37
Former	35 (17.2)	41 (20.2)
Never	130 (63.7)	133 (65.5)
Body mass index
Underweight	7 (3.4)	3 (1.5)	0.23
Normal weight	51 (25.0)	62 (30.2)
Overweight	73 (35.8)	60 (29.3)
Obese	73 (35.8)	80 (39.0)
Age at assessment (y)	Mean (SD)
	36.6 (8.01)	36.7 (9.17)	0.84
	Median (min-max)
Age at diagnosis (y)	14.7 (3.0-22.6)
Time since diagnosis (y)	20.6 (10.7-45.6)
Anthracyclines (n = 156) mg/m²	157.2 (91.0-400.0)∗
IV methotrexate (n = 85) mg/m²	123.2 (20.3-167.7)
Bleomycin (n = 58) mg/m²	35.6 (5.0-95.0)
Corticosteroids (n = 140) mg/m²	2240 (250-4480)
Vincristine (n=182) mg/m²	45.9 (9.2-151.2)
Cyclophosphamides (n=113) mg/m²	3655 (1332-22 889)†
Chest Radiation (n=204) Gy	26.0 (15.0-45.0)
Neck Radiation (n=204) Gy	26.0 (15.0-51.0)
	N (%)
Relapsed	14 (6.9)
Diagnosed with second malignancy	48 (24.0)

	Survivors N = 204	Controls N = 205	P value
	n (%)	n (%)	P value
Sex
Male	97 (47.5)	99 (48.3)	0.88
Female	107 (52.5)	106 (51.7)
Race
White	172 (84.3)	176 (85.9)	0.66
Other	32 (15.7)	29 (14.1)
Smoking Status
Current	39 (19.1)	29 (14.3)	0.37
Former	35 (17.2)	41 (20.2)
Never	130 (63.7)	133 (65.5)
Body mass index
Underweight	7 (3.4)	3 (1.5)	0.23
Normal weight	51 (25.0)	62 (30.2)
Overweight	73 (35.8)	60 (29.3)
Obese	73 (35.8)	80 (39.0)
Age at assessment (y)	Mean (SD)
	36.6 (8.01)	36.7 (9.17)	0.84
	Median (min-max)
Age at diagnosis (y)	14.7 (3.0-22.6)
Time since diagnosis (y)	20.6 (10.7-45.6)
Anthracyclines (n = 156) mg/m²	157.2 (91.0-400.0)∗
IV methotrexate (n = 85) mg/m²	123.2 (20.3-167.7)
Bleomycin (n = 58) mg/m²	35.6 (5.0-95.0)
Corticosteroids (n = 140) mg/m²	2240 (250-4480)
Vincristine (n=182) mg/m²	45.9 (9.2-151.2)
Cyclophosphamides (n=113) mg/m²	3655 (1332-22 889)†
Chest Radiation (n=204) Gy	26.0 (15.0-45.0)
Neck Radiation (n=204) Gy	26.0 (15.0-51.0)
	N (%)
Relapsed	14 (6.9)
Diagnosed with second malignancy	48 (24.0)

Max, maximum; min, minimum; SD, standard deviation.

∗

Anthracycline equivalent dose.

†

Cyclophosphamide equivalent dose.

Table 2.

Mean age-adjusted neurocognitive z scores of survivors and controls

Domain	Survivors	Controls	FDR P
Domain	Mean (SD)	Mean (SD)	FDR P
Attention
Focused	0.35 (0.95)	0.54 (0.84)	0.061
Span	0.04 (1.01)	0.22 (0.92)	0.085
Sustained	-0.10 (1.35)	0.23 (0.89)	0.011
Variability	-0.23 (1.11)	-0.03 (1.05)	0.089
Processing Speed
Reaction time	-0.16 (1.17)	-0.04 (0.99)	0.29
Visuomotor	0.13 (0.96)	0.40 (0.94)	0.011
Visual	0.27 (0.98)	0.62 (0.97)	0.002
Motor	-0.38 (1.05)	-0.01 (0.90)	0.001
Memory
Verbal learning	-0.08 (1.04)	0.31 (1.02)	0.001
Short-term recall	-0.24 (1.01)	0.12 (1.04)	0.002
Long-term recall	-0.30 (1.14)	0.08 (1.10)	0.002
Selective reminding	-0.18 (1.11)	-0.03 (0.96)	0.17
Executive Function
Working memory	-0.08 (0.93)	0.05 (0.86)	0.16
Self-monitoring	-0.00 (1.14)	0.20 (0.95)	0.085
Cognitive flexibility	-0.02 (1.26)	0.26 (1.11)	0.033
Fluency	-0.05 (1.20)	0.03 (1.05)	0.47

Domain	Survivors	Controls	FDR P
Domain	Mean (SD)	Mean (SD)	FDR P
Attention
Focused	0.35 (0.95)	0.54 (0.84)	0.061
Span	0.04 (1.01)	0.22 (0.92)	0.085
Sustained	-0.10 (1.35)	0.23 (0.89)	0.011
Variability	-0.23 (1.11)	-0.03 (1.05)	0.089
Processing Speed
Reaction time	-0.16 (1.17)	-0.04 (0.99)	0.29
Visuomotor	0.13 (0.96)	0.40 (0.94)	0.011
Visual	0.27 (0.98)	0.62 (0.97)	0.002
Motor	-0.38 (1.05)	-0.01 (0.90)	0.001
Memory
Verbal learning	-0.08 (1.04)	0.31 (1.02)	0.001
Short-term recall	-0.24 (1.01)	0.12 (1.04)	0.002
Long-term recall	-0.30 (1.14)	0.08 (1.10)	0.002
Selective reminding	-0.18 (1.11)	-0.03 (0.96)	0.17
Executive Function
Working memory	-0.08 (0.93)	0.05 (0.86)	0.16
Self-monitoring	-0.00 (1.14)	0.20 (0.95)	0.085
Cognitive flexibility	-0.02 (1.26)	0.26 (1.11)	0.033
Fluency	-0.05 (1.20)	0.03 (1.05)	0.47

Means and SDs presented as age-adjusted z scores, with population mean = 0 and SD = 1.0.

FDR, P, false discovery rate–adjusted P-values for multiple comparisons between survivors and control; SD, standard deviation.

Phillips NS, Mulrooney DA, Williams AM, et al. Neurocognitive impairment associated with chronic morbidity in long-term survivors of Hodgkin Lymphoma. Blood Adv. 2023;7(23):7270-7278.

Contents

Data & Figures

Supplemental data

References

Cited By

Email alerts

ASH Publications

American Society of Hematology

Phillips NS, Mulrooney DA, Williams AM, et al. Neurocognitive impairment associated with chronic morbidity in long-term survivors of Hodgkin Lymphoma. Blood Adv. 2023;7(23):7270-7278.

Contents

Data & Figures

Supplemental data

References

Related

Related

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only